Comparison of cardiovascular events in two treatment
groups
Initiated with PCSK-9 inhibitor combined with statins significantly
reduce the incidence of cardiovascular events versus statins treatment
(incidence 2.07% vs 8.29%, hazard ratio, 0.24, 95% CI, 0.12-0.51,
P<0.0001) (Figure 2). The results showed lower risk of
re-hospitalization (adjusted HR, 0.09; 95%CI, 0.03-0.31;P <0.001, figure 3), but there’re no difference in TVR,
MI and re-angina between two groups. All prognostic subgroups received
benefit from the PCSK-9 inhibitor combined statin treatment, while male
patients treated by PCSK-9 inhibitor had a lower risk of cardiovascular
events than those treated by statin w/wo other lipid lowering therapies
(Figure 4).